News

NATROX® O₂ Now Available in South Korea

We are pleased to announce the Ministry of Food & Drug Safety (MFDS) has granted approval to ship and sell our groundbreaking product NATROX® O₂ topical oxygen therapy into South Korea. A newly added NATROX® distribution partner in South Korea, KOVE Inc., was instrumental in getting the product registered in its country. This milestone marks the first time patients in South Korea will access this leading-edge medical device, bringing new hope to those suffering from chronic wounds.

“We’re thrilled to introduce NATROX® O₂ to the South Korean market together with our new partner, KOVE,” said Craig Kennedy, CEO of NATROX® Wound Care.  “This marks a significant milestone in our journey to revolutionize wound care on a global scale. We’re confident NATROX® O₂ will be a game-changer for wound care in the country.”